

Bishal Gyawali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1170355/publications.pdf>

Version: 2024-02-01

219
papers

6,382
citations

136740

32
h-index

85405

71
g-index

224
all docs

224
docs citations

224
times ranked

11988
citing authors

#	ARTICLE	IF	CITATIONS
1	Knowledge, attitude, preventive practices and utilization of cervical cancer screening among women in Nepal: a community-based cross-sectional study. <i>European Journal of Cancer Prevention</i> , 2022, 31, 73-81.	0.6	6
2	Health System Preparedness for COVID-19 and Its Impacts on Frontline Health-Care Workers in Nepal: A Qualitative Study Among Frontline Health-Care Workers and Policy-Makers. <i>Disaster Medicine and Public Health Preparedness</i> , 2022, 16, 2560-2568.	0.7	21
3	Trends in drug revenue among major pharmaceutical companies: A 2010â€2019 cohort study. <i>Cancer</i> , 2022, 128, 311-316.	2.0	9
4	Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs. <i>The Lancet Regional Health Americas</i> , 2022, 7, 100157.	1.5	9
5	Radiographic progression-free survival in the ACIS trial for prostate cancer. <i>Lancet Oncology</i> , The, 2022, 23, e4.	5.1	1
6	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	0.8	6
7	Global consequences of the US FDA's accelerated approval of cancer drugs. <i>Lancet Oncology</i> , The, 2022, 23, 201-203.	5.1	9
8	Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1518-1521.	0.8	9
9	Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. <i>European Journal of Cancer</i> , 2022, , .	1.3	4
10	Community-based management of chronic obstructive pulmonary disease in Nepalâ€”Designing and implementing a training program for Female Community Health Volunteers. <i>PLOS Global Public Health</i> , 2022, 2, e0000253.	0.5	0
11	Progression-free survival: it is time for a new name. <i>Lancet Oncology</i> , The, 2022, 23, 328-330.	5.1	24
12	Should the control arms of randomized trials have an expiry date?. <i>Nature Reviews Clinical Oncology</i> , 2022, , .	12.5	5
13	Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. <i>Current Oncology</i> , 2022, 29, 2530-2538.	0.9	1
14	Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptorâ€”Positive, <i>ERBB2</i>-Negative Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2022, 5, e224361.	2.8	2
15	Cancer treatments should benefit patients: a common-sense revolution in oncology. <i>Nature Medicine</i> , 2022, 28, 617-620.	15.2	14
16	Cancer Groundshot: Building a Robust Cancer Control Platform in Addition To Launching the Cancer Moonshot. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 100-115.	1.8	3
17	Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. <i>JAMA Oncology</i> , 2022, 8, 879.	3.4	14
18	Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. <i>JCO Global Oncology</i> , 2022, , .	0.8	2

#	ARTICLE	IF	CITATIONS
19	Training General Practitioners in Oncology: A Needs Assessment Survey From Nepal. JCO Global Oncology, 2022, , .	0.8	1
20	Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?. Journal of Clinical Oncology, 2022, 40, 3103-3105.	0.8	3
21	A needs assessment survey to inform a general practitioner in oncology (GPO) training program in Nepal.. Journal of Clinical Oncology, 2022, 40, 11024-11024.	0.8	0
22	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. JAMA Network Open, 2022, 5, e2216183.	2.8	27
23	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Global Oncology, 2022, , .	0.8	2
24	Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. JCO Oncology Practice, 2022, 18, e1164-e1169.	1.4	13
25	Globalization of oncology clinical trials: Which lower-middle and upper-middle income countries are participating?. Journal of Clinical Oncology, 2022, 40, e13512-e13512.	0.8	0
26	Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	2.3	4
27	Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics. Journal of Clinical Oncology, 2021, 39, 175-177.	0.8	22
28	The need for locally generated data in haematology: a real-world experience of aplastic anaemia in Nepal. British Journal of Haematology, 2021, 192, e63-e65.	1.2	1
29	First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population. JCO Oncology Practice, 2021, 17, e1537-e1550.	1.4	6
30	A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer. EClinicalMedicine, 2021, 32, 100730.	3.2	9
31	Effectiveness of a Female Community Health Volunteer-Delivered Intervention in Reducing Blood Glucose Among Adults With Type 2 Diabetes. JAMA Network Open, 2021, 4, e2035799.	2.8	15
32	FDA approval standards for anticancer agents – lessons from two recent approvals in breast cancer. Nature Reviews Clinical Oncology, 2021, 18, 397-398.	12.5	4
33	An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. JAMA Oncology, 2021, 7, 379.	3.4	81
34	Epidemiologic Pattern of Cancer in Kathmandu Valley, Nepal: Findings of Population-Based Cancer Registry, 2018. JCO Global Oncology, 2021, 7, 443-452.	0.8	9
35	Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Seminars in Oncology, 2021, 48, 141-144.	0.8	14
36	Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. Current Oncology, 2021, 28, 1518-1527.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. <i>JAMA Internal Medicine</i> , 2021, 181, 499.	2.6	28
38	Risk-Stratifying Treatment Strategies for Febrile Neutropenia—Tools, Tools Everywhere, and Not a Single One That Works?. <i>JCO Oncology Practice</i> , 2021, 17, OP.21.00148.	1.4	9
39	Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. <i>JAMA Internal Medicine</i> , 2021, 181, 490.	2.6	32
40	Why Not Adore ADAURA?—The Trial We Need vs the Trial We Got. <i>JAMA Oncology</i> , 2021, 7, 677.	3.4	12
41	Differences in cancer incidence and pattern between urban and rural Nepal: one-year experience from two population-based cancer registries. <i>Ecancermedalscience</i> , 2021, 15, 1229.	0.6	4
42	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. <i>JAMA Oncology</i> , 2021, 7, 728.	3.4	94
43	Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	4
44	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets. <i>Journal of Cancer Policy</i> , 2021, 28, 100283.	0.6	5
45	Oncology training programmes for general practitioners: a scoping review. <i>Ecancermedalscience</i> , 2021, 15, 1241.	0.6	9
46	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021, 6, 100117.	2.0	37
47	An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e1-e12.	1.8	62
48	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021, 4, 396-404.	2.6	30
49	Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. <i>Targeted Oncology</i> , 2021, 16, 415-424.	1.7	6
50	Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. <i>European Journal of Cancer</i> , 2021, 150, 203-210.	1.3	5
51	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. <i>International Journal of Cancer</i> , 2021, 149, 1455-1462.	2.3	16
52	Text Messaging in Cancer-Supportive Care: A Systematic Review. <i>Cancers</i> , 2021, 13, 3542.	1.7	7
53	Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway. <i>JAMA Internal Medicine</i> , 2021, 181, 1275.	2.6	34
54	A systematic review and meta-analysis of non-adherence to anti-diabetic medication: Evidence from low- and middle-income countries. <i>International Journal of Clinical Practice</i> , 2021, 75, e14717.	0.8	19

#	ARTICLE	IF	CITATIONS
55	Atezolizumab in Metastatic Triple-Negative Breast Cancer—No Contradiction in the Eyes of a Dispassionate Observer. <i>JAMA Oncology</i> , 2021, 7, 1285.	3.4	8
56	Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. <i>BMJ</i> , The, 2021, 374, n1959.	3.0	40
57	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. <i>Lancet Oncology</i> , The, 2021, 22, 1367-1377.	5.1	69
58	Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity?. <i>Ecancermedicalsecience</i> , 2021, 15, 1301.	0.6	1
59	Do Editorialists With Industry-Related Conflicts of Interest Write Unduly Favorable Editorials for Cancer Drugs in Top Journals?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1258-1263.	2.3	6
60	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. <i>JAMA Internal Medicine</i> , 2021, 181, 1596-1604.	2.6	14
61	Not an “either/or”: Integrating mental health and psychosocial support within non-communicable disease prevention and care in humanitarian response. <i>Journal of Global Health</i> , 2021, 11, 03119.	1.2	6
62	A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. <i>Journal of the National Cancer Institute</i> , 2020, 112, 335-342.	3.0	16
63	Prevalence of American Heart Association defined ideal cardiovascular health metrics in Nepal: findings from a nationally representative cross-sectional study. <i>International Health</i> , 2020, 12, 325-331.	0.8	15
64	Pesticide exposure and diabetes mellitus in a semi-urban Nepali population: a cross-sectional study. <i>International Archives of Occupational and Environmental Health</i> , 2020, 93, 513-524.	1.1	5
65	Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma. <i>JAMA Oncology</i> , 2020, 6, 296.	3.4	11
66	Barriers and facilitators to cervical cancer screening uptake among women in Nepal—a qualitative study. <i>Women and Health</i> , 2020, 60, 963-974.	0.4	13
67	Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. <i>EClinicalMedicine</i> , 2020, 20, 100269.	3.2	102
68	Gender differences in outcomes of cancer patients with COVID: Signal or noise?. <i>EClinicalMedicine</i> , 2020, 26, 100535.	3.2	1
69	Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials. <i>EClinicalMedicine</i> , 2020, 25, 100458.	3.2	10
70	Building Strong Primary Health Care to Tackle the Growing Burden of Non-Communicable Diseases in Nepal. <i>Global Health Action</i> , 2020, 13, 1788262.	0.7	12
71	Clinical Trial End Points in Severe COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1578-1580.	1.4	2
72	Endpoints used in phase III randomized controlled trials of treatment options for COVID-19. <i>EClinicalMedicine</i> , 2020, 23, 100403.	3.2	32

#	ARTICLE	IF	CITATIONS
73	Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities. JCO Global Oncology, 2020, 6, 1211-1217.	0.8	26
74	Burden of Diabetes and Prediabetes in Nepal: A Systematic Review and Meta-Analysis. Diabetes Therapy, 2020, 11, 1935-1946.	1.2	39
75	Evaluating Vitamin D levels in Rheumatic Heart Disease patients and matched controls: A case-control study from Nepal. PLoS ONE, 2020, 15, e0237924.	1.1	1
76	A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries. Lancet Haematology, 2020, 7, e638-e639.	2.2	18
77	Addressing the Mental Health Challenges of Cancer Care Workers in LMICs During the Time of the COVID-19 Pandemic. JCO Global Oncology, 2020, 6, 1490-1493.	0.8	10
78	COVID-19 and cancer: do we really know what we think we know?. Nature Reviews Clinical Oncology, 2020, 17, 386-388.	12.5	35
79	Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine, 2020, 21, 100332.	3.2	80
80	When Is a Suboptimal Approach to Cancer Screening Better Than None?. AMA Journal of Ethics, 2020, 22, E93-101.	0.4	1
81	Challenges and opportunities for cancer clinical trials in low- and middle-income countries. Nature Cancer, 2020, 1, 142-145.	5.7	18
82	Covid-19 Pandemic—An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology?. JAMA Oncology, 2020, 6, 1693.	3.4	14
83	Risk of COVID-19 in Patients With Cancer. JAMA Oncology, 2020, 6, 1471.	3.4	5
84	Real-world evidence and regulatory drug approval. Nature Reviews Clinical Oncology, 2020, 17, 271-272.	12.5	24
85	Application of single-level and multi-level modeling approach to examine geographic and socioeconomic variation in underweight, overweight and obesity in Nepal: findings from NDHS 2016. Scientific Reports, 2020, 10, 2406.	1.6	15
86	Fall in US cancer death rates: Time to pop the champagne?. EClinicalMedicine, 2020, 19, 100279.	3.2	6
87	Breast cancer early detection: A phased approach to implementation. Cancer, 2020, 126, 2379-2393.	2.0	261
88	Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.. Journal of Clinical Oncology, 2020, 38, 2071-2071.	0.8	2
89	Mismatch between mortality burden and number of FDA registration trials in highly lethal cancers.. Journal of Clinical Oncology, 2020, 38, 2072-2072.	0.8	2
90	Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis. Ecancermedicalscience, 2020, 14, 1091.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 36-43.	2.3	21
92	An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19303-e19303.	0.8	0
93	Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber. <i>Ecancermedalscience</i> , 2020, 14, ed104.	0.6	4
94	Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber. <i>Ecancermedalscience</i> , 2020, 14, ed104.	0.6	5
95	Title is missing!. , 2020, 15, e0237924.		0
96	Title is missing!. , 2020, 15, e0237924.		0
97	Title is missing!. , 2020, 15, e0237924.		0
98	Title is missing!. , 2020, 15, e0237924.		0
99	Title is missing!. , 2020, 15, e0237924.		0
100	Title is missing!. , 2020, 15, e0237924.		0
101	The burden and correlates of multiple cardiometabolic risk factors in a semi-urban population of Nepal: a community-based cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 15382.	1.6	10
102	Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs. <i>JAMA Network Open</i> , 2019, 2, e199570.	2.8	13
103	Lung Cancer Survival Gains: Contributions of Academia and Industry. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 465-467.	0.4	2
104	Challenges and Opportunities for Biomarker Validation. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 357-361.	0.4	9
105	Combating non-communicable diseases: potentials and challenges for community health workers in a digital age, a narrative review of the literature. <i>Health Policy and Planning</i> , 2019, 34, 55-66.	1.0	38
106	Low levels of ideal cardiovascular health in a semi-urban population of Western Nepal: a population-based, cross-sectional study. <i>Heart Asia</i> , 2019, 11, e011131.	1.1	5
107	Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. <i>JAMA Internal Medicine</i> , 2019, 179, 906.	2.6	189
108	May Measurement Month 2017: an analysis of blood pressure screening results in Nepalâ€™South Asia. <i>European Heart Journal Supplements</i> , 2019, 21, D83-D85.	0.0	7

#	ARTICLE	IF	CITATIONS
109	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 374-387.	1.8	19
110	Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer. Journal of Global Oncology, 2019, 5, 1-8.	0.5	32
111	Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival. JAMA Network Open, 2019, 2, e193684.	2.8	6
112	Cardio-metabolic disease risk factors among South Asian labour migrants to the Middle East: a scoping review and policy analysis. Globalization and Health, 2019, 15, 33.	2.4	16
113	Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. Journal of Clinical Oncology, 2019, 37, 1863-1867.	0.8	76
114	US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology. JAMA Oncology, 2019, 5, 607.	3.4	7
115	Causes, Consequences, and Control of High Cancer Drug Prices. , 2019, , 39-57.		1
116	Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. Oncologist, 2019, 24, e397-e399.	1.9	33
117	Making adjuvant therapy decisions with uncertain data. Annals of Oncology, 2019, 30, 361-364.	0.6	14
118	Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. BMJ Open, 2019, 9, e033728.	0.8	17
119	Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ: British Medical Journal, 2019, 366, l5221.	2.4	117
120	Is the number of cancer drug approvals a surrogate for regulatory success?. Journal of Cancer Policy, 2019, 22, 100202.	0.6	15
121	Does <i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer increase all-cause mortality?. International Journal of Cancer, 2019, 144, 411-412.	2.3	10
122	Association between age and sex and mortality after adjuvant therapy for renal cancer. Cancer, 2019, 125, 1637-1644.	2.0	11
123	Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment. Annals of Oncology, 2019, 30, 96-102.	0.6	30
124	Association between progression-free survival and patients' quality of life in cancer clinical trials. International Journal of Cancer, 2019, 144, 1746-1751.	2.3	62
125	The promise of ESCAT: a new system for evaluating cancer drug-target pairs. Nature Reviews Clinical Oncology, 2019, 16, 147-148.	12.5	9
126	Community-based interventions for prevention of Type 2 diabetes in low- and middle-income countries: a systematic review. Health Promotion International, 2019, 34, 1218-1230.	0.9	15

#	ARTICLE	IF	CITATIONS
127	Plasma vs Tissue Next-Generation Sequencing in Non-“Small Cell Lung Cancer” Either, Both, or Neither?. JAMA Oncology, 2019, 5, 148.	3.4	7
128	Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment, 2019, 173, 103-109.	1.1	38
129	Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.. Journal of Clinical Oncology, 2019, 37, 395-395.	0.8	2
130	Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 760-762.	2.3	0
131	The US Food and Drug Administration’s Approval of Adjuvant Sunitinib for Renal Cell Cancer. JAMA Oncology, 2018, 4, 623.	3.4	17
132	Cancer groundshot: going global before going to the moon. Lancet Oncology, The, 2018, 19, 288-290.	5.1	24
133	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. JAMA Oncology, 2018, 4, 343.	3.4	130
134	Does global oncology need artificial intelligence?. Lancet Oncology, The, 2018, 19, 599-600.	5.1	12
135	Pemetrexed in Nonsquamous Non-“Small Cell Lung Cancer. JAMA Oncology, 2018, 4, 17.	3.4	11
136	Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. Oncologist, 2018, 23, 367-374.	1.9	14
137	Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review. Journal of Global Oncology, 2018, 4, 1-8.	0.5	7
138	Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007-2016. JNCI Cancer Spectrum, 2018, 2, pky016.	1.4	12
139	Efficacy, Safety, and Regulatory Approval of Food and Drug Administration’s “Designated Breakthrough and Nonbreakthrough Cancer Medicines. Journal of Clinical Oncology, 2018, 36, 1805-1812.	0.8	72
140	What Global Oncology Needs: Mutual Learning and More Funding. Journal of Global Oncology, 2018, 4, 1-3.	0.5	5
141	A2070 The prevalence and burden of multiple cardio metabolic risk factors in semi-urban population in Nepal. Journal of Hypertension, 2018, 36, e19.	0.3	0
142	A2780 Association between body mass index among children aged 10-15 years and socio-economic status of their household in selected schools of Lekhnath, Nepal. Journal of Hypertension, 2018, 36, e282.	0.3	0
143	A3811 Low levels of ideal cardiovascular health among adults in a semi-urban area of Western Nepal. Journal of Hypertension, 2018, 36, e127.	0.3	0
144	Meta-analyses and RCTs in oncology-what is the right balance?. Lancet Oncology, The, 2018, 19, 1565-1566.	5.1	4

#	ARTICLE	IF	CITATIONS
145	Rethinking community based strategies to tackle health inequities in South Asia. BMJ: British Medical Journal, 2018, 363, k4884.	2.4	9
146	ReDO_DB: the repurposing drugs in oncology database. Ecancermedalscience, 2018, 12, 886.	0.6	86
147	Cancer treatment in the last 6 months of life: when inaction can outperform action. Ecancermedalscience, 2018, 12, 826.	0.6	6
148	A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. Ecancermedalscience, 2018, 12, 847.	0.6	31
149	Awareness, prevalence, treatment, and control of type 2 diabetes in a semi-urban area of Nepal: Findings from a cross-sectional study conducted as a part of COBIN-D trial. PLoS ONE, 2018, 13, e0206491.	1.1	37
150	Community-based intervention for management of diabetes in Nepal (COBIN-D trial): study protocol for a cluster-randomized controlled trial. Trials, 2018, 19, 579.	0.7	14
151	Duration of adjuvant immunotherapy—biologic, clinical and economic considerations. Medical Oncology, 2018, 35, 160.	1.2	9
152	Reporting harms more transparently in trials of cancer drugs. BMJ: British Medical Journal, 2018, 363, k4383.	2.4	23
153	Information Transparency in the Drug Approval Process—Reply. JAMA Oncology, 2018, 4, 1622.	3.4	0
154	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. JAMA Oncology, 2018, 4, 1553.	3.4	1,260
155	Negative phase 3 randomized controlled trials: Why cancer drugs fail the last barrier?. International Journal of Cancer, 2018, 143, 2079-2081.	2.3	10
156	Reinforcing the social compromise of accelerated approval. Nature Reviews Clinical Oncology, 2018, 15, 596-597.	12.5	23
157	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors. JAMA Network Open, 2018, 1, e180416.	2.8	45
158	Diabetes management training for female community health volunteers in Western Nepal: an implementation experience. BMC Public Health, 2018, 18, 641.	1.2	22
159	Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia. Bone Marrow Transplantation, 2018, 53, 1288-1294.	1.3	36
160	Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.. Journal of Clinical Oncology, 2018, 36, 6573-6573.	0.8	2
161	Does the oncology community have a rejection bias when it comes to repurposed drugs?. Ecancermedalscience, 2018, 12, ed76.	0.6	9
162	A prospective survey of comprehensive score for financial toxicity (COST) in Japanese cancer patients.. Journal of Clinical Oncology, 2018, 36, e22128-e22128.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Drugs that lack single-agent activity: are they worth pursuing in combination?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 193-194.	12.5	25
164	Economics of Cancer Medicines: For Whose Benefit?. <i>New Bioethics</i> , 2017, 23, 95-104.	0.5	39
165	Combining drugs and extending treatment – a PFS end point is not sufficient. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 521-522.	12.5	16
166	Rushing will not help to choose the best combination. <i>Lancet Oncology</i> , The, 2017, 18, e186.	5.1	0
167	Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 691-692.	0.8	3
168	Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials. <i>Annals of Oncology</i> , 2017, 28, 898-899.	0.6	24
169	Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant. <i>Future Oncology</i> , 2017, 13, 935-944.	1.1	3
170	FDA Approval Summary: Sonidegib – Letter. <i>Clinical Cancer Research</i> , 2017, 23, 5993-5993.	3.2	1
171	Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 60, 18-23.	3.4	48
172	Ischemic Stroke and Impact of Thyroid Profile at Presentation: A Systematic Review and Meta-analysis of Observational Studies. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 2926-2934.	0.7	27
173	Me-too drugs with limited benefits – the tale of regorafenib for HCC. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 653-654.	12.5	17
174	Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 859-862.	2.3	12
175	Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. <i>Annals of Oncology</i> , 2017, 28, 246-253.	0.6	19
176	Human Trafficking in Nepal: Post-Earthquake Risk and Response. <i>Disaster Medicine and Public Health Preparedness</i> , 2017, 11, 153-154.	0.7	10
177	Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	22
178	Low-value practices in oncology contributing to financial toxicity. <i>Ecancermedalscience</i> , 2017, 11, 727.	0.6	19
179	Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. <i>Journal of Global Oncology</i> , 2017, 3, 93-97.	0.5	23
180	The OlympiAD trial: who won the gold?. <i>Ecancermedalscience</i> , 2017, 11, ed75.	0.6	7

#	ARTICLE	IF	CITATIONS
181	Cancer drugs in LMICs: cheap but unaffordable. <i>Oncotarget</i> , 2017, 8, 89425-89426.	0.8	7
182	The incidence and risks of adverse events in randomized controlled trials (RCTs) of cancer drugs downplaying the harms.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14036-e14036.	0.8	0
183	Biosimilars in oncology: everybody agrees but nobody uses?. <i>Recenti Progressi in Medicina</i> , 2017, 108, 172-174.	0.8	1
184	Negative trials in ovarian cancer: is there such a thing as too much optimism?. <i>Ecancermedicalsecience</i> , 2016, 10, ed58.	0.6	7
185	Loss of muscle mass associated with the long term use of mTOR inhibitors. <i>Annals of Oncology</i> , 2016, 27, vii87.	0.6	0
186	Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Global Oncology</i> , 2016, 2, 145-153.	0.5	15
187	Challenges in diabetes mellitus type 2 management in Nepal: a literature review. <i>Global Health Action</i> , 2016, 9, 31704.	0.7	35
188	Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. <i>Oncology Reports</i> , 2016, 35, 1727-1731.	1.2	71
189	TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. <i>ESMO Open</i> , 2016, 1, e000058.	2.0	5
190	Muscle wasting associated with the long-term use of mTOR inhibitors. <i>Molecular and Clinical Oncology</i> , 2016, 5, 641-646.	0.4	41
191	Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 118-124.	2.0	7
192	Me, Too. <i>Journal of Global Oncology</i> , 2016, 2, 99-104.	0.5	13
193	Same Data; Different Interpretations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3729-3732.	0.8	6
194	Should low-income countries invest in breast cancer screening?. <i>Cancer Causes and Control</i> , 2016, 27, 1341-1345.	0.8	20
195	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
196	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
197	Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal. <i>British Journal of Haematology</i> , 2016, 173, 941-942.	1.2	3
198	Prevalence and correlates of psychological distress symptoms among patients with substance use disorders in drug rehabilitation centers in urban Nepal: a cross-sectional study. <i>BMC Psychiatry</i> , 2016, 16, 314.	1.1	25

#	ARTICLE	IF	CITATIONS
199	Use of donated clotting factors for surgeries on haemophilic patients in a resource-constrained country: a kind donor, good outcome, change of practice and future directions. <i>Haemophilia</i> , 2016, 22, e453-5.	1.0	3
200	Geriatric assessment for the evaluation of tolerability to out-patient chemotherapy among elderly cancer patients. <i>Annals of Oncology</i> , 2016, 27, vii61.	0.6	0
201	MPS 06-07 INDOOR USE OF SOLID BIOMASS FUEL AND INCREASES IN BLOOD PRESSURE IN THE MUNICIPALITY OF LEKHNATH, NEPAL. <i>Journal of Hypertension</i> , 2016, 34, e95.	0.3	0
202	Chemotherapy in locally advanced head and neck squamous cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016, 44, 10-16.	3.4	32
203	Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 492-494.	13.9	48
204	Antifungal prophylaxis with Amphotericin B deoxycholate emulsified in lipids for acute myeloid leukemia patients treated in low economy countries. <i>Leukemia and Lymphoma</i> , 2016, 57, 474-476.	0.6	1
205	Disparities in the availability of and access to antiemetics recommended by the international antiemetic guidelines in Serbia, Japan, and Nepal. <i>Journal of Clinical Oncology</i> , 2016, 34, 117-117.	0.8	1
206	Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura. <i>Journal of the Nepal Medical Association</i> , 2016, 55, 16-21.	0.1	7
207	Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016. <i>Ecancermedalscience</i> , 2016, 10, ed59.	0.6	0
208	Discordance between the results and conclusions of ICON7. <i>Lancet Oncology</i> , The, 2015, 16, e478.	5.1	2
209	Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report. <i>Oncology Letters</i> , 2015, 10, 972-974.	0.8	16
210	Prevalence of type 2 diabetes in Nepal: a systematic review and meta-analysis from 2000 to 2014. <i>Global Health Action</i> , 2015, 8, 29088.	0.7	63
211	Survival of patients with metastatic breast cancer with or without locoregional therapy. <i>Lancet Oncology</i> , The, 2015, 16, e586.	5.1	1
212	Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians. <i>Journal of Palliative Medicine</i> , 2015, 18, 977-980.	0.6	6
213	Flaws in the trial design of IFCT-0802. <i>Annals of Oncology</i> , 2015, 26, 2003.	0.6	1
214	Opioid-induced constipation. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1331-1338.	0.6	22
215	Some Questions on the Randomized Controlled Trial of Communication Skills Training for Oncologists. <i>Journal of Clinical Oncology</i> , 2015, 33, 222-222.	0.8	6
216	Effective approaches to improve the psychosocial work environment. <i>International Journal of Medical Science and Public Health</i> , 2015, 4, 1.	0.2	5

#	ARTICLE	IF	CITATIONS
217	Cancer care and research in India: what does it mean to Nepal?. Lancet Oncology, The, 2014, 15, e299-e300.	5.1	4
218	Prevalence of Hypertension in Member Countries of South Asian Association for Regional Cooperation (SAARC). Medicine (United States), 2014, 93, e74.	0.4	127
219	Cervical cancer screening in Nepal: ethical considerations. Medicolegal and Bioethics, 0, , 1.	1.7	7